The Use of Botulinum Toxin to Control Low Back Pain
DOI:
https://doi.org/10.25759/spmfr.379Keywords:
Botulinum Toxins/therapeutic use, Botulinum Toxins, Type A/therapeutic use, Low Back Pain/drug therapy, Low Back Pain/rehabilitationAbstract
Introduction: Low back pain is the most prevalent musculoskeletal disorder, affecting 40%-80% of individuals worldwide, representing a major disability factor in quality of life and enormous costs for the society. The present review aims to reflect on scientific evidence that evaluates the role of botulinum toxin (BT) as a treatment of low back pain.
Methods: The present study is a systematic review. The authors reviewed the literature indexed in the databases Medline (via PubMed), Web of Science and CENTRAL. To achieve study purposes, only randomized clinical trials (RCT) were included, with at least 2 months of follow-up, appropriate sample size and in line with the standards of the Delphi List.
Results: In the evidence contemplated, BT therapy proved to be superior in pain control and in the improvement of functional capacity when compared with placebo. On the other hand, the treatment of BT + physiotherapy showed more effectiveness versus 1) placebo + physiotherapy and versus 2) therapy of infiltrations with corticosteroid and local anesthetic (triamcinolone and lidocaine) + physiotherapy, regarding pain control of low back pain.
Conclusion: Even though the approached studies indicate the important role of BT in low back pain management, the consolidation of these conclusions need scientific evidence with higher quality, larger randomized clinical trials, standardization of the evaluated outcomes and detailed intervention protocols. BT therapy, integrated in a multimodal approach, may be a relevant asset in the management of low back pain.
Downloads
References
Cunha-Miranda L, Carnide F, Lopes MF. Prevalence of rheumatic occupational diseases - PROUD study. Acta Reumatol Port. 2010;35:215-26.
Gouveia N, Rodrigues A, Eusebio M, Ramiro S, Machado P, Canhão H, et al. Prevalence and social burden of active chronic low back pain in the adult Portuguese population: results from a national survey. Rheumatol Int. 2016; 36:183-97.
Meucci RD, Fassa AG, Faria NM. Prevalence of chronic low back pain: systematic review. Rev Saude Publica. 2015; 49.
Machado D, Kumar A, Jabbari B. Abobotulinum Toxin A in the Treatment of Chronic Low Back Pain. Toxins. 2016;8:374. doi: 10.3390/toxins8120374
Ney JP, Difazio M, Sichani A, Monacci W, Foster L, Jabbari B. Treatment of chronic low back pain with successive injections of botulinum toxin a over 6 months: a prospective trial of 60 patients. Clin J Pain. 2006; 22:363-9.
Grochowski CO, Cartmill M, Reiter J, Spaulding J, Haviland J, Valea F, et al. Anxiety in first year medical students taking gross anatomy. Clin Anat. 2014;27:835-8. doi: 10.1002/ca.22398.
Allegri M, Montella S, Salici F, Valente A, Marchesini M, Compagnone C, Baciarello M, Manferdini ME, Fanelli G. Mechanisms of low back pain: a guide for diagnosis and therapy. F1000Research 2016; 5.
Amirdelfan K, McRoberts P, Deer TR. The differential diagnosis of low back pain: a primer on the evolving paradigm. Neuromodulation. 2014; 17:11-7.
Dagenais S, Tricco AC, Haldeman S. Synthesis of recommendations for the assessment and management of low back pain from recent clinical practice guidelines. Spine J. 2010;10:514-29.
Grewal H, Grewal BS, Patel R. Nonsurgical interventions for low back pain. Primary Care. 2012;39:517-23.
National Institute for Health and Care Excellence. Clinical Guidelines: Low Back Pain and Sciatica in Over 16s: Assessment and Management. London: National NICE; 2016.
Chou R, Huffman LH. Evaluation and Management of Low Back Pain. 2011.
Qaseem A, Wilt TJ, McLean RM, Forciea MA. Noninvasive Treatments for Acute, Subacute, and Chronic Low Back Pain: A Clinical Practice Guideline From the American College of Physicians. Annals of internal medicine 2017.
Gerwin R. Botulinum toxin treatment of myofascial pain: a critical review of the literature. Curr Pain Headache Rep. 2012;16:413-22.
Singh JA. Botulinum toxin therapy for osteoarticular pain: an evidencebased review. Ther Adv Musculoskelet Dis. 2010;2:105-18. doi: 10.1177/1759720X09357113.
Yoon SJ, Song SH, Kim YJ, Kang HY, Lee SH. Biomechanical Evaluation of Refractory Chronic Low Back Pain Treatment with Botulinum Toxin Type A. J Musculoskelet Pain. 2014; 22:152-9.
Godoy IR, Donahue DM, Torriani M. Botulinum toxin injections in musculoskeletal disorders. Semin Musculoskelet Radiol. 2016;20:441-52. doi: 10.1055/s-0036-1594284.
Zhang T, Adatia A, Zarin W, Moitri M, Vijenthira A, Chu R, et al. The efficacy of botulinum toxin type A in managing chronic musculoskeletal pain: a systematic review and meta analysis. Inflammopharmacology. 2011;19:21-34.
Wheeler A, Smith HS. Botulinum toxins: mechanisms of action, antinociception and clinical applications. Toxicology. 2013;306:124-46.
Barbano RL. Botulinum toxins in clinical practice: Gaps in knowledge. Neurol Clin Pract. 2016; 6:206-8.
Durand A, Serment G. Toxines botuliques: utilisation pratique. Ann Readapt Med Phys. 2003;46:386-8. doi: 10.1016/s0168-6054(03)00131-4.
Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015; 4:1.
Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015; 349:g7647.
Verhagen AP, de Vet HC, de Bie RA, Kessels AG, Boers M, Bouter LM, et al. The Delphi list: a criteria list for quality assessment of randomized clinical trials for conducting systematic reviews developed by Delphi consensus. J Clin Epidemiol. 1998; 51:1235-41.
De Andres J, Adsuara VM, Palmisani S, Villanueva V, Lopez-Alarcon MD. A double-blind, controlled, randomized trial to evaluate the efficacy of botulinum toxin for the treatment of lumbar myofascial pain in humans. Reg Anesth Pain Med. 2010;35:255-60. doi: 10.1097/AAP.0b013e3181d23241.
Fishman LM, Anderson C, Rosner B. BOTOX and physical therapy in the treatment of piriformis syndrome. Am J Phys Med Rehabil. 2002;81:936-42. doi: 10.1097/00002060-200212000-00009.
Foster L, Clapp L, Erickson M, Jabbari B. Botulinum toxin A and chronic low back pain: a randomized, double-blind study. Neurology. 2001;56:1290-3.
Jazayeri SM, Ashraf A, Fini HM, Karimian H, Nasab MV. Efficacy of botulinum toxin type a for treating chronic low back pain. Anesthesiol Pain Med. 2011; 1:77-80.
Chou R, Loeser JD, Owens DK, Rosenquist RW, Atlas SJ, Baisden J, et al. Interventional therapies, surgery, and interdisciplinary rehabilitation for low back pain: an evidence-based clinical practice guideline from the American Pain Society. Spine. 2009; 34:1066-77.
Gobel H, Heinze A, Reichel G, Hefter H, Benecke R. Efficacy and safety of a single botulinum type A toxin complex treatment (Dysport) for the relief of upper back myofascial pain syndrome: results from a randomized doubleblind placebo-controlled multicentre study. Pain. 2006;125:82-8.
Nagarajan V, Al-Shubaili A, Ayad YM, Alexander J, Al-Ramezi K. Low back ache treatment with botulinum neurotoxin type A. Local experience in Kuwait. Med Princ Pract. 2007;16:181-6. doi: 10.1159/000100387.
Yoon SJ, Ho J, Kang HY, Lee SH, Kim KI, Shin WG, et al. Low-dose botulinum toxin type A for the treatment of refractory piriformis syndrome. Pharmacotherapy. 2007; 27:657-65.
Bakheit AM. The possible adverse effects of intramuscular botulinum toxin injections and their management. Curr Drug Saf. 2006;1:271-9. doi: 10.2174/157488606777934431.
Crowner BE, Torres-Russotto D, Carter AR, Racette BA. Systemic weakness after therapeutic injections of botulinum toxin a: a case series and review of the literature. Clin Neuropharmacol. 2010; 33:243-7.
Bernstein IA, Malik Q, Carville S, Ward S. Low back pain and sciatica: summary of NICE guidance. BMJ. 2017, 356:i6748.
Soares A, Andriolo RB, Atallah AN, da Silva EM. Botulinum toxin for myofascial pain syndromes in adults. Cochrane Database Syst Rev. 2014;2014:CD007533. doi: 10.1002/14651858.CD007533.pub3.
Waseem Z, Boulias C, Gordon A, Ismail F, Sheean G, Furlan AD. Botulinum toxin injections for low-back pain and sciatica. Cochrane Database Syst Rev. 2011:CD008257. doi: 10.1002/14651858.CD008257.pub2.
Downloads
Published
How to Cite
Issue
Section
License
Copyright statement
Authors must also submit a copyright statement (as seen below) on article submission.
To the Editor-in-chief of the SPMFR Journal:
The below signed author(s) hereby state that the article
________________________________________ (ref. MFR_________) is
an original unpublished work and all facts stated are a product of the author(s) investigation. This article does not violate any copyright laws or privacy statements. The author(s) also hereby confirm that there is no conflict of interest's issues in this article.
By submitting this article the author(s) agree that after publication all copyrights belong to the SPMFR Journal.
Signed by all authors
Date:
Names (capital letters):
Signatures:
The SPMFR Journal’s contents are follow a Creative Commons licence. After publication the authors can hand out the articles as long as the SPMFR Journal is credited.
